Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01951586
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01951586 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2013
Completion date
November 28, 2017
Enrollment
226 (actual)
Sites
74

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer